Explanipedia

SquiDBase: a community resource of raw nanopore data from microbes Open

Wim L. Cuypers, Halil İbrahim ceylan, Eline Turcksin, Laura Raes, Nicky de Vrij , et al. · 2025

Experimental data-driven research relies on raw data, which consist of unprocessed experimental outputs, whereas derived data are transformed through a number of processing steps to reveal specific insights. Such processing, however, can p…

Serological Evidence of Cryptic Rift Valley Fever Virus Transmission Among Humans and Livestock in Central Highlands of Kenya Open

Silvia Situma, Evans Otieno Omondi, Luke Nyakarahuka, Raymond Odinoh, Marshal M. Mweu , et al. · 2024

Although the highlands of East Africa lack the geo-ecological landmarks of Rift Valley fever (RVF) disease hotspots to participate in cyclic RVF epidemics, they have recently reported growing numbers of small RVF clusters. Here, we investi…

COVID-19 vaccine responses are influenced by distinct risk factors in naive and SARS-CoV-2 experienced hemodialysis recipients Open

Nicolas Gemander, Delphine Kemlin, Stéphanie Depickère, Natasha S. Kelkar, Shilpee Sharma , et al. · 2024

Hybrid Immunity Overcomes Defective Immune Response to COVID-19 Vaccination in Kidney Transplant Recipients Open

Nicolas Gemander, Delphine Kemlin, Stéphanie Depickère, Natasha S. Kelkar, Pieter Pannus , et al. · 2023

Presymptomatic viral shedding in high‐risk mpox contacts: A prospective cohort study Open

Isabel Brosius, Christophe Van Dijck, Jasmine Coppens, Leen Vandenhove, Eugene Bangwen , et al. · 2023

The risk of infection after exposure to clade IIb mpox virus (MPXV) is unknown, and potential presymptomatic shedding of MPXV remains to be demonstrated. High‐risk contacts of mpox patients were followed‐up in a prospective longitudinal co…

Five accelerated schedules for the tick-borne encephalitis vaccine FSME-Immun® in last-minute travellers: an open-label, single-centre, randomized controlled pilot trial Open

Nicole Berens‐Riha, Petra Andries, Annelies Aerssens, Quentin Ledure, Yolien Van Der Beken , et al. · 2023

Background The purpose of this exploratory study was to evaluate different accelerated tick-borne encephalitis (TBE) vaccine schedules for last-minute travellers. Methods In a single-centre, open-label pilot study, 77 TBE-naïve Belgian sol…

Third dose of COVID-19 mRNA vaccine closes the gap in immune response between naïve nursing home residents and healthy adults Open

Pieter Pannus, Stéphanie Depickère, Delphine Kemlin, Daphnée Georges, Sarah Houben , et al. · 2023

Validation of a Reporter Cell Line for Flavivirus Inhibition Assays Open

Tatiana M. T. Rezende, Gabriella Macera, Leo Heyndríckx, Johan Míchiels, Sandra Coppens , et al. · 2023

The Hec1a-IFNB-Luc reporter cell line allows the detection of all 10 flaviviruses tested, including the 4 dengue virus serotypes. Its use for serodiagnostic purposes, measuring neutralizing antibody activity in sera, and the assessment of …

Humoral and cellular immune correlates of protection against COVID-19 in kidney transplant recipients Open

Delphine Kemlin, Nicolas Gemander, Stéphanie Depickère, Véronique Olislagers, Daphnée Georges , et al. · 2023

Alternative sampling specimens for the molecular detection of mpox (formerly monkeypox) virus Open

Jasmine Coppens, Fien Vanroye, Isabel Brosius, Laurens Liesenborghs, Saskia van Henten , et al. · 2022

Safety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): A single blind, randomized, non-inferiority trial Open

Pieter Pannus, Stéphanie Depickère, Delphine Kemlin, Sarah Houben, Kristof Y. Neven , et al. · 2022

Fractional dosing of COVID-19 vaccines could accelerate vaccination rates in low-income countries. Dose-finding studies of the mRNA vaccine BNT162b2 (Pfizer-BioNTech) suggest that a fractional dose induces comparable antibody responses to …

Severe mpox (formerly monkeypox) disease in five patients after recent vaccination with MVA-BN vaccine, Belgium, July to October 2022 Open

Nicole Berens‐Riha, Tessa de Block, Jojanneke Rutgers, Johan Míchiels, Liesbeth Van Gestel , et al. · 2022

Vaccination is important in containing the 2022 mpox (formerly monkeypox) epidemic. We describe five Belgian patients with localised severe symptoms of proctitis and penile oedema, occurring between 4 and 35 days after post-exposure preven…

Pre- and asymptomatic viral shedding in high-risk contacts of monkeypox cases: a prospective cohort study Open

Isabel Brosius, Christophe Van Dijck, Jasmine Coppens, Leen Vandenhove, Eugene Bangwen , et al. · 2022

A bstract Epidemiological data suggest that clade IIb monkeypox virus (MPXV) is readily transmitted during sexual contact, even before symptom onset. However, presymptomatic shedding of MPXV remains to be demonstrated. Here, we prospective…

Humoral and cellular immune correlates of protection against COVID-19 in kidney transplant recipients Open

Delphine Kemlin, Nicolas Gemander, Stéphanie Depickère, Véronique Olislagers, Daphnée Georges , et al. · 2022

As solid organ recipients are at high risk of severe COVID-19 and respond poorly to primary SARS-CoV-2 mRNA vaccination, they have been prioritized for booster vaccination. However, an immunological correlate of protection has not been ide…

Retrospective detection of asymptomatic monkeypox virus infections among male sexual health clinic attendees in Belgium Open

Irith De Baetselier, Christophe Van Dijck, Chris Kenyon, Jasmine Coppens, Johan Míchiels , et al. · 2022

A dual-antigen self-amplifying RNA SARS-CoV-2 vaccine induces potent humoral and cellular immune responses and protects against SARS-CoV-2 variants through T cell-mediated immunity Open

Séan Mc Cafferty, A.K.M. Ashiqul Haque, Aster Vandierendonck, Brian Weidensee, Magalie Plovyt , et al. · 2022

Safety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): a single blind, randomized, non-inferiority trial Open

Pieter Pannus, Stéphanie Depickère, Delphine Kemlin, Sarah Houben, Kristof Y. Neven , et al. · 2022

1 Abstract Background The use of fractional dose regimens of COVID-19 vaccines has the potential to accelerate vaccination rates in low-income countries. Dose-finding studies of the mRNA vaccine BNT162b2 (Pfizer-BioNTech) have suggested th…

Three doses of BNT162b2 vaccine confer neutralising antibody capacity against the SARS-CoV-2 Omicron variant Open

Kevin K. Ariën, Leo Heyndríckx, Johan Míchiels, Katleen Vereecken, Kurt Van Lent , et al. · 2022

Antibody response against SARS-CoV-2 Delta and Omicron variants after third-dose BNT162b2 vaccination in allo-HCT recipients Open

Lorenzo Canti, Kevin K. Ariën, Isabelle Desombere, Stéphanie Humblet‐Baron, Pieter Pannus , et al. · 2022

Asymptomatic Monkeypox Virus Infections Among Male Sexual Health Clinic Attendees in Belgium Open

Irith De Baetselier, Christophe Van Dijck, Chris Kenyon, Jasmine Coppens, Dorien Van den Bossche , et al. · 2022

Three doses of the BNT162b2 vaccine confer neutralising antibody capacity against the SARS-CoV-2 B.1.1.529 (Omicron) variant of concern Open

Kevin K. Ariën, Leo Heyndríckx, Johan Míchiels, Katleen Vereecken, Kurt Van Lent , et al. · 2021

We report the levels of neutralising antibodies against Wuhan, Delta and Omicron variants in healthy individuals pre-infected or not with SARS-CoV-2 and immunized with three doses of the BNT162b2 vaccine. Our observations support the rapid…

Poor Antibody Response to BioNTech/Pfizer Coronavirus Disease 2019 Vaccination in Severe Acute Respiratory Syndrome Coronavirus 2–Naive Residents of Nursing Homes Open

Pieter Pannus, Kristof Y. Neven, Stéphane De Craeye, Leo Heyndríckx, Sara Vande Kerckhove , et al. · 2021

Background Residents of nursing homes (NHs) are at high risk of coronavirus disease 2019 (COVID-19)–related disease and death and may respond poorly to vaccination because of old age and frequent comorbid conditions. Methods Seventy-eight …

Predictors of neutralizing antibody response to BNT162b2 vaccination in allogeneic hematopoietic stem cell transplant recipients Open

Lorenzo Canti, Stéphanie Humblet‐Baron, Isabelle Desombere, Julika Neumann, Pieter Pannus , et al. · 2021

A dynamic mucin mRNA signature associates with COVID-19 disease presentation and severity Open

Annemieke Smet, Tom Breugelmans, Johan Míchiels, Kevin Lamote, Wout Arras , et al. · 2021

BACKGROUNDSARS-CoV-2 infection induces mucin overexpression, further promoting disease. Given that mucins are critical components of innate immunity, unraveling their expression profiles that dictate the course of disease could greatly enh…

Dynamics of the Magnitude, Breadth and Depth of the Antibody Response at Epitope Level Following Dengue Infection Open

Francesca Falconi‐Agapito, Karen Kerkhof, Xiomara Merino, Johan Míchiels, Marjan Van Esbroeck , et al. · 2021

Dengue is a major public health problem in tropical and sub-tropical regions worldwide. Since the Zika epidemic and the increased co-circulation of other arboviruses, the serology-based diagnosis of dengue has become more problematic due t…

Evaluation of a surrogate virus neutralization test for high-throughput serosurveillance of SARS-CoV-2 Open

Joachim Mariën, Johan Míchiels, Leo Heyndríckx, Antoine Nkuba-Ndaye, Ann Ceulemans , et al. · 2021

Poor antibody response to BioNTech/Pfizer COVID-19 vaccination in SARS-CoV-2 naïve residents of nursing homes Open

Pieter Pannus, Kristof Y. Neven, Stéphane De Craeye, Leo Heyndríckx, Sara Vande Kerckhove , et al. · 2021

Background Residents of nursing homes (NH) are at high risk of COVID-19 related morbidity and death and may respond poorly to vaccination because of old age and frequent comorbidities. Methods Forty residents and forty staff members either…

Evaluation of a surrogate virus neutralization test for high-throughput serosurveillance of SARS-CoV-2 Open

Joachim Mariën, Johan Míchiels, Leo Heyndríckx, Antoine Nkuba-Ndaye, Ann Ceulemans , et al. · 2021

High-throughput serological tests that can detect neutralizing antibodies against SARS-CoV-2 are desirable for serosurveillance and vaccine efficacy evaluation. Although the conventional neutralization test (cVNT) remains the gold standard…

Evaluating SARS-CoV-2 spike and nucleocapsid proteins as targets for antibody detection in severe and mild COVID-19 cases using a Luminex bead-based assay Open

Joachim Mariën, Ann Ceulemans, Johan Míchiels, Leo Heyndríckx, Karen Kerkhof , et al. · 2020

Large-scale serosurveillance of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) will only be possible if serological tests are sufficiently reliable, rapid and affordable. Many assays are either labour-intensive and requi…

Evaluating SARS-CoV-2 spike and nucleocapsid proteins as targets for IgG antibody detection in severe and mild COVID-19 cases using a Luminex bead-based assay Open

Joachim Mariën, Johan Míchiels, Leo Heyndríckx, Karen Kerkhof, Nikki Foqué , et al. · 2020

Large-scale serosurveillance of severe acute respiratory syndrome coronavirus type 2 (SARS- CoV-2) will only be possible if serological tests are sufficiently reliable, rapid and inexpensive. Current assays are either labour-intensive and …

Johan Míchiels YOU? Author Swipe